Create Account | Sign In: Author or Forum

Search Symptoms

Category: Endocrinology | Family Medicine | Geriatrics | Gynecology | Internal Medicine | Nursing | Orthopedics | Pharmacy | Radiology | Rheumatology | Surgery | Journal

Back to Journal Articles

Longer Bisphosphonate Use May Up Atypical Femur Fracture Risk

Last Updated: August 20, 2020.

Longer duration of bisphosphonate use is associated with an increased risk for atypical femur fracture, according to a study published in the Aug. 20 issue of the New England Journal of Medicine.

THURSDAY, Aug. 20, 2020 (HealthDay News) -- Longer duration of bisphosphonate use is associated with an increased risk for atypical femur fracture, according to a study published in the Aug. 20 issue of the New England Journal of Medicine.

Dennis M. Black, Ph.D., from the University of California in San Francisco, and colleagues studied women aged 50 years or older who received bisphosphonates. Women were followed from Jan. 1, 2007, to Nov. 30, 2017, for the primary outcome of atypical femur fracture.

The researchers found that 277 atypical femur fractures occurred among 196,129 women. There was an increase in the risk for atypical fracture with a longer duration of bisphosphonate use after multivariable adjustment, with hazard ratios of 8.86 and 43.51 for three years to less than five years and for eight years or more, respectively, compared with less than three months. Race, height, weight, and glucocorticoid use were also risk factors. Discontinuation of bisphosphonate use was associated with a rapid decline in atypical fracture risk. During one to 10 years of bisphosphonate use, decreases in the risk for osteoporotic and hip fractures outweighed the increased risk for atypical fractures among whites, but less so among Asians. In whites, 149 hip fractures were prevented and two bisphosphonate-associated atypical fractures occurred after three years compared with 91 and eight fractures, respectively, in Asians.

"These results in a diverse cohort contribute to existing but limited evidence about the risks and benefits of treatment in individual patients or populations," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)


Previous: SARS-CoV-2 Nasopharyngeal Load Higher in Children Than Adults Next: Evinacumab Cuts LDL-C Level in Familial Hypercholesterolemia

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: